Tumor cell‐derived vaccines: Advances, challenges, and future prospects
Bibliographic record
Abstract
Abstract Tumors pose an enormous burden to human health due to their high incidence and mortality rates, constituting a major global public health concern. Tumor immunotherapy is a revolutionary treatment for patients with complicated conditions or for those who have not responded well to conventional treatment. Vaccine technology effectively prevents infectious diseases, and tumor vaccines have been recently demonstrated to have significant potential as a tumor therapy. Antigens for tumor vaccines can be derived from several different types of tumor cell materials, including entire cells, cell lysates, cell vesicles, and cell membranes. The selection and optimization of antigens are critical for vaccine effectiveness, as they should trigger a precise immune system defensive response against a specific pathogen (or cells) without producing overwhelming negative side effects. They should precisely trigger the immune system's defensive responses against specific pathogens or cells without producing overwhelming negative side effects. Supported by a robust theoretical basis and substantial preclinical evidence, tumor cell‐derived vaccines hold considerable potential for future research and clinical translation. This review introduces the current state of tumor cell‐derived vaccines, discusses their limitations, and explores future pathways to their advancement. Tumor cell‐derived vaccines may emerge as a novel strategy for the treatment of cancer, allowing patients to have more effective treatment options.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.003 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".